Cullinan Therapeutics wins FDA orphan drug designation for CLN-049 in relapsed AML
PUBT · 3d ago
Share
Listen to the news
- Cullinan Therapeutics received FDA Orphan Drug Designation for CLN-049 in relapsed or refractory acute myeloid leukemia.
- CLN-049 is an investigational FLT3xCD3 T-cell engager in a Phase 1 program.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cullinan Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605190700PRIMZONEFULLFEED9722297) on May 19, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending